Please assess the completion status of the following clinical trial:

Trial Title: Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any adult (≥ 18 years of age) who has ESRD and a prevalent or incident tunneled hemodialysis catheter and expected to continue hemodialysis for 3 months will be eligible for enrollment.~Exclusion Criteria:~* The following patients will be excluded from study entry:~  1. patient is unable (and no guardian or legal representative is available) or unwilling to provide informed consent and~ 2. patient is allergic to NAC, tigecycline, minocycline, or heparin.~The following patients will be excluded from randomization:~1. patient has evidence of a complicated bacteremia such as endocarditis, septic thrombophlebitis, septic emboli, osteomyelitis, deep seated abscess, or hypotension requiring use of vasopressors,~2. patient has evidence of an exit site infection around the catheter such as a pus pocket, purulent drainage, or erythema,~3. patient is pregnant or will become pregnant,~4. the infection is due to an organism that is resistant to tigecycline such as Candida or Pseudomonas species.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- NAC/Tigecycline/Heparin combination lock solution (Type: EXPERIMENTAL): A combination of the above three drugs will form the catheter lock solution that will be instilled into the catheter
- Standard anticoagulant (heparin or citrate) (Type: PLACEBO_COMPARATOR): Standard anticoagulant (heparin or citrate)

Based on this trial design, predict the completion outcome and termination type (if applicable).